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Osteoradionecrosis (ORN) of the jaw is a significant complication of radiotherapy for oral cavity cancer. In addition
to antibiotic medication, treatment options such as hyperbaric oxygen therapy, surgical approaches, and combined
therapy with pentoxifylline and tocopherol have been recently introduced.
In this review article, we will discuss the definition and classifications of osteoradionecrosis, its etiology and
pathophysiology, previous treatment options, oral and maxillofacial complications of radiotherapy, basic information
on pentoxifylline and tocopherol, recent reports of pentoxifylline and tocopherol combined therapy, and, finally,
ORN-induced animal models and future approaches.
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Osteoradionecrosis (ORN) of the jaw is one of the main
complications of radiotherapy, and results in alteration
of the shape and function of the oral cavity and jaw that
causes substantial deterioration in patient quality of life
(Figure 1). Although the incidence of ORN has declined re-
cently with the advancement in radiation techniques and
increased focus on the predisposing factors for ORN, the
pathogenesis and pathophysiology of ORN remain unclear,
and its risk factors have not completely been elucidated.
Pentoxifylline has been marketed in Europe for the
management of vascular disorders such as intermittent
claudication, and has been found to act against some in-
flammatory mediators including TNF-α. Alpha-tocopherol,
as named vitamin E, scavenges free radicals generated dur-
ing oxidative stress and protects cell membranes against
lipid peroxidation [1,2]. Given these well-known anti-
oxidant properties of tocopherol, these two drugs have
recently been reported to be potent and synergistic anti-
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unless otherwise stated.During our investigations of the pathophysiology of
ORN in a radiation-induced animal model with a tissue
engineering approach [3], we noticed the efficacy of com-
bined pentoxifylline and tocopherol therapy. To advance
the knowledge of biomaterial applications in the treatment
of ORN, this article is intended to provide a review of
the current trends for conservative treatment in ORN of
the jaw.Review
Osteoradionecrosis
Based on clinical findings, ORN of the jaw can be de-
fined as irradiated bone that becomes devitalized and ex-
posed through overlying skin or mucosa without healing
for three months, without recurrence of cancer. Two cri-
teria in the definition, the duration of exposure and the
meaning of devitalization, have been controversial. ORN
has been defined as “when bone in the radiation field is
exposed for at least 2 months in the absence of local
neoplastic disease”, “an area greater than 1 cm of ex-
posed bone in a field of irradiation that fails to show any
evidence of healing for at least 6 months” [4,5], “an area
of exposed mandible present for longer than 2 months
in a previously irradiated field, in the absence of recur-
rent tumor” [5,6], “an ulceration of the mucous mem-
brane with exposure of necrotic bone”, and “irradiated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Clinical views of surgical approaches in an ORN patient, including the identification and resection of the necrotic mandible
with associated soft tissues (A, B), the harvesting of the composite fibular free flap from the left lower leg of the patient (C), and a
two-week post-operative view of the patient (D).
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the overlying skin or mucosa, persisting without healing
for 3 months in the absence of tumor recurrence” [1,7].
Generally, a duration of four to six weeks can be ac-
cepted (Figure 2), and devitalization can be defined as
radiologic findings of bony necrosis through histologic
confirmation of necrotic bone within the radiation field
[8,9]. ORN has also been described as radiation osteitis,
radio-osteonecrosis, radiation osteomyelitis, osteomyelitis
of irradiated bone, osteonecrosis, radio-osteomyelitis,
septic osteoradionecrosis, and post-radiotherapy osteo-
necrosis [1].
The incidence of ORN after radiotherapy for head and
neck cancers has been reported to be due to the loss of
soft tissue, which naturally recovers, and the exposure of
necrotic bone for over 6 months. The prevalence rate
also varies widely, from less than 1% to as high as 30%,
with a range of 10 to 15% reported in most literature. ORN
affects the mandible more often than the maxilla, with an
incidence between 2% and 22% [1,10]. The disorder is rare
after radiation of less than 60 Gy, but more common when
brachytherapy is used, and less common after hyperfractio-
nated radiotherapy at 72 to 80 Gy, or after moderately ac-
celerated fractionated radiotherapy with a boost of 64 to 72
Gy [1,11]. The incidence of ORN may be higher for con-
current chemotherapy and radiotherapy (CCRT), whereas
it may be lower for intensity-modulated radiotherapy
(IMRT) [1,12-14]. The basic characteristics of ORN are
summarized in Table 1.
There are many different staging systems for ORN that
have been published for clinical treatment and research
(Tables 2, 3 and 4) [4,8,15]. These classifications were
based on various criteria, such as soft tissue dehiscence,
necrotic bone, oro-cutaneous fistula and pathologic frac-
ture. Marx’s staging system is perhaps the most widelyFigure 2 Schematic timetables of the duration of the latent period, aused and is predicated on staging ORN based on re-
sponse to treatment [4].
The diagnosis of ORN is based primarily on clinical
signs and symptoms. Ulceration or necrosis of the mucous
membrane with exposure of necrotic bone is frequent and
accompanied by neurologic symptoms of pain, dysesthesia
or anesthesia, which may be present in the distribution of
the inferior alveolar nerve in the mandible. Associated
symptoms of fetor oris, dysgeusia, and food impaction
may also be found. Exposure of rough, irregular denuded
bone may result in physical irritation to the adjacent
tissues, and progression of these conditions may lead to
pathologic fracture and intra- or extraoral fistula forma-
tions. Functional disturbances with limitations in mouth
opening and difficulties in mastication, deglutition and
speech may also occur [8].
Etiology and pathophysiology of osteoradionecrosis
Regaud published the first report on ORN of the jaw
after radiotherapy in 1922, and Ewing reported in 1926
on the bone changes associated with radiation therapy
and described this disease state as “radiation osteitis”
[1,16]. In 1938, Watson and Scarborough described this
radiation osteitis as caused by radiation, trauma and in-
fection. Trauma to the soft tissues overlying bone in the
oral cavity induced bacteria to enter into the underlying
demineralized bone and lead to osteomyelitis [1,17].
Meyer classified ORN as a special type of osteomyelitis
in 1970 [1,18]. In 1972, Daly focused on the role of trauma
in ORN and on the surface contaminant role of microor-
ganisms, which is not the true etiological cause of ORN.
In 1983, Marx redefined the pathophysiology of ORN by
proposing that radiation therapy induces an endarteritis
that results in tissue hypoxia, hypocellularity, and hypo-
vascularity, which in turn causes tissue breakdown andnd the onset of osteoradionecrosis.
Table 1 Characteristics, risk factors, conservative and
surgical treatment of ORN [9-13]
Osteoradionecrosis of jaw
Characteristics
Irradiated bone becomes devitalized and exposed
through the overlying skin or mucosa without
healing for 3months, without recurrence of tumor
Most case happen in mandible
70-94% of cases developed within the first 3 years
after radiotherapy
Risk factors
Hyperfractionated irradiation regimen - High total
dose (6000-7000cGy)
Recent reports have suggested that when
chemotherapy is added to radiotherapy the
incidence of ORN may be increased
Pre-irradiation and post-irradiation dental
extractions
Poor oral hygien with periodontal disease










Segmental resection and Free flap reconstruction
Table 3 Classification of ORN by Epstein et al. [7]
Stage Description Symtoms Treatment
















IIb Pathologic fracture Jaw dysfunction





IIIa No pathologic fracture
IIIb Pathologic fracture Jaw dysfunction
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gested from their histopathologic findings on specimens
after sequestrectomy and resection that radiation-induced
obliteration of the inferior alveolar artery was the domin-
ant factor leading to ischemic necrosis of the mandible.
Harris introduced the use of ultrasound as a modality to
treat ORN in 1992 [7].
For the critical appraisal of the pathophysiology of
ORN, associated risk factors of ORN can be investigated,
including the primary site of cancer (more commonly
the posterior mandible due to its dense bony nature),
proximity of tumor to bone, extent of the mandible in-
cluded in the primary radiation field, poor oral hygiene
including odontogenic and periodontal disease, state of
dentition, radiation dose above 60 Gy, nutritional status,
concomitant chemo-radiation, chronic trauma from ill-
fitting prostheses, and acute trauma from surgical proce-
dures of the jaw.Table 2 Classification of ORN by Marx [1]
Stage Description
I Exposed alveolar bone without pathologic fracture,
which responds to hyperbaric oxygen therapy
II Disease does not respond to HBOT, and requires
sequestrectomy and saucerization
III Full thickness bone damage or pathologic fracture, usually
requires complete resection and reconstruction with free tissueThere are some theories proposing that ORN is not a
primary infection of irradiated bone, but rather a complex
metabolic and tissue homeostatic deficiency created by
radiation-induced cellular injury. Meyer proposed a theory
involving radiation, trauma and infection and reported
that oral microbiological flora invade the underlying irra-
diated bone after injury [1]. Endothelium, bone, and peri-
osteum are all important tissues that have been shown to
become hypoxic, hypocellular and hypovascular as a result
of ORN [19]. With this theory, the classic sequence of
radiation, trauma and infection can be replaced by a se-
quence of metabolic and cellular changes as cellular death
and collagen lysis exceed synthesis and cellular replication,
resulting in chronic non-healing wounds [4].
Recently, a new theory known as the “fibro-atrophic
theory” has emerged, and proposes that fibroblast popu-
lations not only undergo total cellular depletion in re-
sponse to radiation exposure, but also show a reduced
ability to produce and secrete collagen into the sur-
rounding tissue. This theory is based on the concept
that osteoclasts suffer radiation damage earlier than the
development of vascular alterations [1,20]. Accordingly,Table 4 Classification of ORN by Notani et al. [14]
Grade Description
I ORN confined to alveolar bone
II ORN limited to the alveolar bone and/or mandible aboce
the level of the inferior alveolar canal
III ORN involving the mandible below the level of the inferior
alveolar canal and/or skin fistula and/or pathological fracture
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tion and dysregulation of fibroblastic activity that leads
to atrophic tissue within a previously irradiated area. [1]
The histopathologic phases of the development of ORN
include the prefibrotic phase, the constitutive organized
phase, and the late fibroatrophic phase. In the initial prefi-
brotic phase, changes in endothelial cells predominate,
along with the acute inflammatory response; in the consti-
tutive organized phase, abnormal fibroblastic activity pre-
dominates, and there is disorganization of the extracellular
matrix; in the late fibroatrophic phase, tissue remodeling
occurs along with the formation of fragile healed tissues
that carry a serious inherent risk of late reactivated inflam-
mation in the event of local injury [20,21].
After radiotherapy, the endothelial cells are injured both
from direct radiation damage and from indirect damage
by radiation-generated reactive oxygen species or free rad-
icals. Injured endothelial cells produce chemotactic cyto-
kines that trigger an acute inflammatory response and
then generate a further release of reactive oxygen species
from polymorphs and other phagocytes. The destruction
of endothelial cells, coupled with vascular thrombosis,
lead to necrosis of microvessels, local ischemia, and tissue
loss. Loss of the natural endothelial cell barrier results in
the excretion of various cytokines that cause fibroblasts to
become myofibroblasts [1,22,23].
Previous treatment options of osteoradionecrosis
The management of ORN is difficult and is not always suc-
cessful because of the lack of suitable, effective methods
corresponding to the various lesions of the oral cavity and
jaw accompanied by various risk factors. ORN of the jaw is
usually treated with conservative or surgical management.
Conservative therapies include frequent saline irrigation
and antibiotic medications during infectious periods.
Another conservative approach is hyperbaric oxygen
treatment (HBOT). These treatment options are se-
lected according to the stages of ORN, especially for the
effective treatment of early and advanced ORN. Stage I,
or early stage ORN, is managed conservatively with
therapies such as local wound care, HBOT, and antibiotic
medications. Stage III, advanced stage ORN, is managed
surgically with wide resection and immediate micro-
vascular reconstruction. For stage II, intermediate stage
ORN, it is difficult to recommend a definitive treatment
procedure [20,24-26].
Antibiotic medications should always be instituted after
bacterial identification and sensitivity testing, and any
delays in surgical treatment should be avoided. Usually,
penicillin with metronidazole or clindamycin is initially
administered until bacterial identification is available. Pre-
vious clinical studies have shown that the polymicrobial
nature of ORN presents with a microflora spectrum that
is very responsive to the therapeutic regimens normallyused to treat odontogenic infections. Consultation with an
infectious disease consultant is especially helpful in cases
involving long durations of treatment [24,27,28].
Surgical approaches for osteoradionecrotic jaws may
encompass a series of procedures, including wound de-
bridement, which involves the removal of infected and
devitalized teeth and associated soft tissues, sequestrec-
tomy, which is the removal of devitalized bony frag-
ments or an involucrum of the jaw, decortication, which
is the removal of lateral and inferior cortical plates of
bone to gain access to the infected medullar cavity, and
resection with health bony margins with immediate or
delayed reconstruction (Figure 3).
HBOT is well known to positively affect surgical out-
comes by promoting angiogenesis in irradiated tissues.
HBOT not only increases the oxygen supply in hypoxic
tissue, thereby inducing fibroblastic proliferation and ca-
pillary formation, but also increases tissue vascularity,
viability and healing capacity [29,30]. HBOT most likely
achieves these effects through a complex series of changes
in affected tissues. Tissue swelling is probably improved
through the osmotic effect of oxygen, and the steep oxy-
gen gradient established across an irradiated tissue margin
leads to the growth of new blood vessels. In addition,
improving oxygen levels improves white blood cell and
fibroblast function, further enhancing wound healing [31].
However, in a randomized control study, HBOT was not
better than placebo [30]. In addition, HBOT was associ-
ated with many adverse effects including pressure-induced
damage to the ears, sinuses and lungs, a temporary
worsening of short sightedness (myopia), claustrophobia
and oxygen poisoning. Thus, the use of HBOT in treat-
ing established ORN has not been convincing and is still
controversial.
The indications for an individual or combined approach
to treating ORN have not been defined [15,32]. Recent un-
derstanding of the pathophysiology of ORN based on the
concept of radiation-induced fibrosis has led to the advent
of new therapeutic regimens composed of pentoxifylline
and tocopherol [33].
Oral and maxillofacial complications of radiotherapy
Radiation-induced damage to the oral and maxillofacial
region is the result of the deleterious effects of therapeutic
radiation on the oral mucosa and the adjacent salivary
glands, maxilla, mandible, teeth, and masticatory muscula-
tures. To prevent these complex complications of radio-
therapy and to improve quality of life in radiation-exposed
patients, cytoprotective drugs, biological response modi-
fiers, improved salivary-sparing radiation techniques, and
extensive surgical approaches have been introduced.
The severity of oral complications of radiotherapy ranges
from superficial, slowly progressive bone erosion to patho-
logical fracture. Patients often present with signs and
Figure 3 A serial panoramic views of various surgical procedures in a left tongue cancer patient after glossectomy with radial forearm
flap reconstruction (A), with a suspicion for ORN after radiotherapy (B), after wound debridement (C), after sequestrectomy (D, E), after
decortication with sequestrectomy (F, G), and reconstruction with a fibular free flap (H).
Table 5 Scoring systems of ORN
Score Event
NCICTC* [31] 0 None
1 Asymptomatic and detected by imaging
only
2 Symptomatic and interfering with function,
but not interfering with activities of daily
living
3 Symptomatic and interfering with activities
of daily living
4 Symptomatic, or disabling
Store & Boysen [9] 0 Mucosal defects only
1 Radiological evidence of necrotic bone with
intact mucosa
2 Positive radiological findings with denuded
bone intra-orally
3 Clinically exposed radionecrotic bone,
verified by imaging techniques, along with
skin fistulas and infection
Glanzmann &
Gratz [47]
1 Bone exposure without signs of infection
and persisting for at least three months
2 Bone exposure with signs of infection or
sequester and without the signs of grade
3 ± 5
3 Bone necrosis treated with mandibular
resection with a satisfactory result
4 Bone necrosis with persisting problems
despite mandibular resection
5 Death due to osteoradionecrosis
*NCICTC: Common Toxicity Criteria of the National Cancer Institute.
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These complications rarely occur in patients who have
been exposed to radiation doses less than 60 Gy and are
more common when brachytherapy is utilized [1,21]. Den-
tal and periodontal disease, dental extraction, surgery, and
trauma are frequently associated with the onset of ORN
[30]. ORN has also been reported to occur spontaneously.
There are a number of risk factors that contribute to and
are associated with the development of ORN.
To define and grade radiation-induced complications,
several classification systems have been developed. The
Common Toxicity Criteria of the National Cancer Institute
(NCICTC) includes ORN as a musculoskeletal side effect
and mainly considers its functional impact. There are also
other scoring systems proposed by Store and Boysen, and
Glanzmann and Gratz (Table 5) [10,34]. These systems
have not yet been fully validated in clinical practice and
modifications are continuing to be proposed.
Pentoxifylline
Pentoxifylline is a tri-substituted methylxanthine de-
rivative chemically designated as 1-(5-oxohexyl)-3,7-
dimethylxanthine, and is a hemorrheologic agent, unlike
theophylline. Its chemical name is 3,7-dihydro-3,7-di-
methyl-1-(5-oxohexyl)-1H-purine-2,6-dione and its mo-
lecular formula is C13H18N4O3 with a molecular mass of
278.3. Pentoxifylline is a white to creamy white crystalline
powder. It is freely soluble in chloroform and methanol,
soluble in water, sparingly soluble in ethanol, sparingly sol-
uble in toluene, and slightly soluble in ether. It has a melt-
ing point of 104 to 107 °C, within a 3°C range [22,23].
Pentoxifylline exerts an anti-tumor necrosis factor
(TNF)-α effect, increases erythrocyte flexibility, vasodi-
lates, inhibits inflammatory reactions in vivo, inhibits
human dermal fibroblast proliferation and extracellular
matrix (ECM) production, and increases collagenase ac-
tivity in vitro. Pentoxifylline and its metabolites improveblood flow by decreasing its viscosity. In patients with
chronic peripheral arterial disease, this effect increases
blood flow to the affected microcirculation and enhances
tissue oxygenation. The usual dosage of pentoxifylline in
extended-release tablet form is 400 mg, three times a day
with meals. While the effect of pentoxifylline may be seen
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continued for at least 8 weeks.
The precise mode of action of pentoxifylline and the
sequence of events leading to clinical improvement are
not yet defined. Pentoxifylline has been shown to increase
leukocyte deformability and to inhibit neutrophil adhesion
and activation in animal and human in vitro studies. Tis-
sue oxygen levels have also been shown to increase signifi-
cantly with therapeutic doses of pentoxifylline in patients
with peripheral arterial disease. Indications for pentoxifyl-
line include the treatment of patients with intermittent
claudication due to chronic occlusive arterial disease of
the limbs. Although pentoxifylline can improve function
and symptoms in the treatment of peripheral vascular dis-
ease, it is not intended to replace more definitive therapy,
such as surgical bypass or removal of arterial obstructions.
Clinical trials have been conducted using either
extended-release pentoxifylline tablets for up to 60 weeks
or immediate-release pentoxifylline capsules for up to 24
weeks. Dosage ranges were 400 mg bid to tid in the tablet
studies and 200 to 400 mg tid in the capsule studies. The
incidence of adverse reactions to pentoxifylline were
less than 1%, and general side effects were not typical.
Digestive and central nervous system side effects are
dose-related. If patients develop these effects, it is rec-
ommended that the dosage be lowered to one tablet bid,
800 mg/day. If side effects persist at this lower dosage,
the administration of pentoxifylline should be discontin-
ued. After its oral administration in aqueous solution,
pentoxifylline is almost completely absorbed. It undergoes
a first-pass effect and its various metabolites appear in
plasma very soon after dosing. Peak plasma levels of the
parent compound and its metabolites are reached within
one hour. The major metabolites are metabolite I (1-[5-
hydroxyhexyl]-3,7-dimethylxanthine) and metabolite V
(1-[3-carboxypropyl]-3,7-dimethylxanthine), and plasma
levels of these metabolites are 5 and 8 times greater
than pentoxifylline, respectively.
Patients on warfarin should undergo more frequent
monitoring of prothrombin times, while patients with
other risk factors complicated by hemorrhage, e.g., re-
cent surgery and peptic ulceration, should have periodic
examinations for bleeding tendencies. In general, dose
selection for elderly patients should be cautious, usually
starting at the low end of the dosing range, reflecting the
greater frequency of decreased hepatic, renal, or cardiac
function, and of concomitant disease or other drug ther-
apy. Safety and effectiveness in pediatric patients have
not yet been established. Pentoxifylline has been used
concurrently with antihypertensive drugs, β blockers, digi-
talis, diuretics, and antiarrhythmics. Small decreases in
blood pressure have been observed, so periodic systemic
blood pressure monitoring is recommended for patients
receiving concomitant antihypertensive therapy. If needed,dosage of antihypertensive agents should be reduced. Con-
comitant administration of pentoxifylline and theophylline-
containing drugs leads to increased theophylline levels and
theophylline toxicity in some individuals. Such patients
should be closely monitored for signs of toxicity and have
their theophylline dosage adjusted as necessary.
Tocopherol
Tocopherols are a class of organic chemical compounds
consisting of various methylated phenols, many of which
have vitamin E activity. Because the compound’s vitamin
activity was first identified in 1936 as a dietary fertility fac-
tor in rats, it was given the name “tocopherol” from the
Greek words “τόκος” (tókos, birth) and “φέρειν”, (phérein,
to bear or carry) meaning “to carry a pregnancy,” with the
ending “-ol” signifying its status as a chemical alcohol.
Tochotrienols are related compounds that also have
tocopherol activity. All of these derivatives with vitamin ac-
tivity may correctly be referred to as “vitamin E”. Tocotrie-
nols have the same methyl structure in its ring and the
same Greek letter-methyl-notation, but differ from tocoph-
erols due to the presence of three double bonds in the
hydrophobic side chain. Whereas tocopherols have three
centers and eight possible stereoisomers per structural for-
mula, the unsaturation of tocotrienol tails has only a single
stereoisomeric carbon and, thus, two possible isomers per
structural formula, one of which occurs naturally. Vitamin
E exists in eight different forms, four tocopherols and four
tocotrienols. All feature a chromane ring, with a hydroxyl
group that can donate a hydrogen atom to reduce free rad-
icals and a hydrophobic side chain that allows for penetra-
tion into biological membranes. Each form has a different
biological activity; the unnatural l-isomers of tocotrienols
lack almost all vitamin activity, and half of the eight pos-
sible isomers of the tocopherols, those with 2S chirality at
the ring-tail junction, also lack vitamin activity. Of the ste-
reoisomers which retain activity, increasing methylation,
especially full methylation to the alpha-form, increases
vitamin activity. Both the tocopherols and tocotrienols
occur in α (alpha), β (beta), γ (gamma) and δ (delta) forms,
determined by the number and position of methyl groups
on the chromanol ring [22,23,35].
Tocopherols and tocotrienols are fat-soluble antioxi-
dants, but also seem to have many other functions in the
body. The functions of endogenous tocopherol are to
scavenge the reactive oxygen species generated during
oxidative stress that escape the activity of in vivo antioxi-
dant enzymes, to protect cell membranes against lipid
peroxidation, and to partly inhibit TGF-ß1 and procolla-
gen gene expression.
Animal models for the treatment of ORN
Various studies have reported the clinical and radiological
features of ORN, but few data are available regarding the
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experimental studies. An animal model would be relevant
for evaluating the histopathologic findings of irradiated
bone, as well as treatments for ORN with tissue engin-
eering biomaterials [36-41]. In an ORN-induced animal
experimental model, osteonecrotic bone cannot be credit
significantly after different radiation treatments. The estab-
lished ORN does not regress spontaneously, and neither
stabilizes nor gradually worsens, and so is notoriously diffi-
cult to manage [1,4]. Exposing animals to dental extraction,
inoculation of infectious microorganisms, tobacco, and
corticosteroids are useful in creating the acute inflamma-
tory reaction associated with radionecrosis.
The present experimental works were designed to in-
vestigate the effects of increasingly high doses of ioniz-
ing radiation on the histologic and radiologic findings of
the jaw in animal models (Figure 4). All experimental
animal ORN models are summarized in Table 6 [42-47].
Recent reports of pentoxifylline and tocopherol combined
therapy
Combined pentoxifylline-tocopherol therapy has been
proven effective in reducing chronic progressive septic
ORN of the mandible. Because there is currently no
standard medical treatment, this approach constitutes a
useful alternative to existing therapies in treating ORN.
These two drugs act synergistically as potent antifibrotic
agents and are available, well tolerated, inexpensive, and
beneficial to the patient. Pentoxifylline is a methylxan-
thine derivative that exerts an negative effect on TNF-α,
increases erythrocyte flexibility, dilates blood vessels, in-
hibits inflammatory reactions in vivo, inhibits the prolif-
eration of human dermal fibroblasts and the production
of extracellular matrix, and increases collagenase activ-
ity in vitro. It is given with tocopherol, which reduces fi-
brosis by scavenging the reactive oxygen species that
were generated during oxidative stress, protecting cell
membranes against the peroxidation of lipids, and par-
tially inhibiting TGF- β1 and the expression of procolla-
gen genes. In animal studies, neither drug alone was
capable of reversing the effects of reactive oxygen spe-
cies [21]. In addition, pentoxifylline or tocopherol aloneFigure 4 An experimental osteoradionecrosis rat model, including the
toluidine blue (C) staining with micro-computed tomogram views (D)were also unable to reverse the development of human
fibrosis. However, these drugs were effective synergistic-
ally as anti-fibrotic agents.
Despite the few reports in the literature on the man-
agement of radiation-induced sequelae, a basic under-
standing of the mechanisms of radiation-induced fibrosis
can be elucidated given its regression after antioxidant
treatment with superoxide dismutase [3,9], as well as
with a combination [11]. Combined treatment induced a
66% regression of the surface area of radiation-induced
fibrosis after 12 months of treatment in a phase II
clinical trial [8]. Similar results were confirmed in an ex-
perimental cutaneomuscular radiation-induced fibrosis
model—a 70% volume regression after six months of
treatments [48], as well as in another randomized clinical
trial [38]. Futran et al. [14] showed that 1,200 mg/day of
pentoxifylline alone accelerated the healing of mucosal
radiation-induced injury in nine of twelve cases of oral
soft tissue necrosis without ORN. On the basis of new
pathologic understandings of radiation-induced fibrosis,
this combination could reverse ORN by reducing the
microscopic fibroatrophic changes associated with the
progressive necrotic process and by stimulating defect-
ive osteoblastic healing [21]. In one woman with an ex-
tensive progressive exteriorized ORN of the sternum,
complete cutaneous and bone healing was obtained with
combined therapy with clodronate, a well-known bis-
phosphonate that inhibits osteoclastic bone destruction
[24,25]. Between June 1995 and January 2002 in another
phase II trial at Saint Louis Hospital in Paris, 18 con-
secutive patients were treated for severe mandible ORN
and chronic persistent ORN with combined therapy,
which was boosted with clodronate in the last eight
more severe cases of active progressive ORN. All pa-
tients showed improvement at 6 months. Sixteen of the
18 patients recovered completely, 14 of whom recovered
within 8 months. The remaining two patients responded
but not as well [1,2]. Over 7 years, all of the patients
were given daily pentoxifylline 800 mg combined with
tocopherol 1,000 IU orally for 6–24 months. The eight
more seriously affected patients were also given clodro-
nate, 1,600 mg/day 5 days a week.apparatus with irradiation (A), and hematoxylin-eosin (B) and
.
Table 6 Rat animal models of osteoradionecrosis
Radiation irradiation
Animal Sample Source Fraction
dose





SD rats 12 Ortho 5.91/7/8.89 5 1d 29.5/35/44.5 Mandible (Left) Mechanical test 56 days - Tchanque-Fossuo et al.
(2011) [19]
SD rats male 10 Brachy 20 7d Mandible (Left) Extraction 21 days Radiology, histology Tamplen et al. (2011) [35]
SD rats 20 Ortho 5.91/7/8.89 5 1d 29.5/35/44.5 Mandible (Left) Histology only 56 days Histology Tchanque-Fossuo et al
(2011) [19]
SD rats male 10 Brachy 30 1 30 Mandible (Left) Extraction 28 days Radiology, histology Cohen et al. (2011) [41]
SD ratsmale 10 Ortho 3.6 10 1d 36 Mandible (Left) DO unilateral 8 weeks Histology Inyang et al. (2010) [43]
Rat hfSRT 15 60 Mandible (Left) DO unilateral 6,12 weeks Radiology , histology Fenner et al. (2010) [40]
Wistar rats male 108 Co60 8 1 8 Mandible (Left) Extraction 10,12 days Histology Hosokawa et al. (2007) [44]
SD rats male 12 Ortho 3.6 10 1d 36 Mandible (Left) DO unilateral 8 weeks Radiology Fregene et al. (2009) [45]
Rats (WKY, Lewis,
Fisher) male
24 Brachy 20 1 20 Mandible (Right) Injection 7 weeks Radiology & histology Springer et al. (2008) [48]
Rats (WKY, Lewis,
Fisher) male
24 Brachy 20 1 20 Mandible (Right) Histology only 100 days Histology Niehoff et al. (2008) [37]
Wistar rats 25 6 MV 15 4 2w 60 Mandible (Left) Histology only 6,12 weeks Histology Fenner et al. (2010) [40]
Wistar rats male 30 Ortho 6 7 2 - 3d 42 Mandible (Right) Histology only 85,141, 253 days Histology Williamson R.A (2007) [29]
SD rats male 60 Co60 2.5/3 18/15 45 Mandible (Bilateral) Bone defect 6, 8 weeks Histology Lorente et al. (1992) [46]
SD rats male 10 Brachy 20 1 20 Mandible (Left) Extraction 28 days Radiology, histology Tamplen et al. (2011) [35]

















Figure 5 Recent treatment options for the management of
osteoradionecrosis of the jaw.
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http://www.biomaterialsres.com/content/18/1/13Clodronate is a new generation bisphosphonate that
inhibits bone resorption by reducing the number and activ-
ity of osteoclasts [1,2]. An ORN-like disease of mandibular
bone has been reported in patients given this treatment for
cancer-associated hypercalcemia or metastatic osteolytic
lesions. Unlike previous bisphosphonates, clodronate has
been shown to act directly on osteoblastic cells by increas-
ing the formation of bone and reducing the proliferation of
fibroblasts [21].
Continuous treatment of patients with combined pen-
toxifylline, tocopherol and clodronate has proven effect-
ive in reducing chronic progressive septic ORN of the
mandible. Because there is currently no standard medical
treatment, this conservative treatment approach consti-
tutes a useful alternative to existing therapies in treating
ORN. All three drugs are available, well tolerated, inex-
pensive, and beneficial to the patient. Questions regarding
the precise synergistic mechanisms of actions of these
drugs will be investigated in a future randomized clin-
ical trial.
Conclusions
Recent advances in the understanding of ORN pathogen-
esis have resulted in a new therapeutic strategy designed
to improve tissue healing with a combination of pentoxi-
fylline and tocopherol. From the published literature on
this topic, mainly consisting of retrospective chart reviews,
we can conclude the treatment options for ORN of the
jaw can be expanded to include combined therapy to ac-
company the three main approaches; antibiotics, surgery
and HBOT (Figure 5). Increasing effects of collagenase
activity of pentoxifyllin with fibrosis inhibition effect oftocopherol will be added to these previous treatment
options. Histopathological and molecular biological ap-
proaches to ORN with radiation-induced fibrosis should
be executed in a well-designed animal experimental model
before ultimately beginning prospective randomized con-
trol trials in the near future.
Histopathological and molecular biological approaches
to ORN with radiation-induced fibrosis should be exe-
cuted in a well-designed animal experimental model
before ultimately beginning prospective randomized
control trials.
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